Christopher James Frankenfield - Chief Financial Officer at Xilio Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Chief Financial Officer
Issuer Symbol
XLO on Nasdaq
All Insider Reports
All Insider Reports

Christopher James Frankenfield - trading volume in the past year for Xilio Therapeutics, Inc.

Holdings reported by Christopher James Frankenfield for Xilio Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Restricted Stock Units 38,750 $57,178 $0.9837 01 Jan 2026 Direct Common Stock
Common Stock 24,766 $15,929 $0.6432 02 Jan 2026 Direct
Stock Option (right to buy) 668,789 31 Dec 2025 Direct Common Stock

Transactions reported by Christopher James Frankenfield for Xilio Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.